Galapagos extends its collaboration with Amgen throughout 2006
Under the terms of the extended agreement, Galapagos' service division BioFocus will continue to provide Amgen with drug discovery expertise for multiple ion channel targets, including assay development, high throughput screening, chemistry and molecular informatics. In return, Galapagos will receive an upfront fee of $2.3 million as a prepayment of FTE costs. Additionally, Galapagos may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses. Should all clinical and commercial events on a program be achieved, potential of event-dependent payments may exceed $30 million.
Additional financial details, target identity, disease areas and commercialization targets were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.